Abstract
Many epidemiological studies have revealed a close relation between left ventricular (LV) hypertrophy and prognosis of patients with cardiovascular diseases, including heart failure with preserved ejection fraction (HFpEF). Hypertension is a leading cause for HFpEF, and depressor therapy is mandatory and effective in the prevention of LV hypertrophy. However, in some of hypertensive patients, LV hypertrophy progresses even after the reduction of blood pressure or in the absence of hypertension. Our and other experimental studies have suggested that LV hypertrophy is not a homogeneous phenomenon, and that there are at least two types in hypertensive heart disease; adaptive and excessive hypertrophy.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
